A company in Baltimore is personalizing cancer therapy by developing patient-derived tumor xenografts in mice to identify the most effective drugs for the patient.
The bump on the back of the mouse is the size of a Tic Tac breath mint, or, possibly, a small pea.
But for Matt Freedman, a New York artist grappling with a rare and deadly neck cancer, the tiny tumor — his tumor — represents a last-ditch hope for a healthy future.
Freedman, 57, who was diagnosed with adenoid cystic carcinoma in 2012, is among a small but growing group of cancer patients turning to a kind of very personalized medicine in which animals serve as stand-ins to treat human disease.
Called mouse avatars in some circles — like the virtual characters in online games — the critters are implanted with pieces of tumor harvested from their human counterparts. They’re then propagated to create a colony of animals in which to test drugs and other treatments that would be too aggressive — or take too long — to attempt in a person.
Read the complete report here: http://nbcnews.to/1hPhMeO
Source: NBC News
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen